tirzepatide cardiovascular outcome outcomes of semaglutide and for patients with type 2 diabetes in clinical practice tirzepatide cardiovascular outcomes trial results

What the evidence shows Consistency across studies: a systematic review spanning 36 studies from 1993 to 2024 found reliable evidence of structural and functional recovery across tendon, ligament, muscle, and bone injury models, with no adverse effects reported at any dose tested, a notably clean safety signal given the study volume (Vasireddi et al., 2025) A specific mechanism in tendon repair: preclinical work found BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts specifically, pointing to a plausible pathway for its effects on connective tissue (Chang et al., 2018) Reach beyond the musculoskeletal system: research has extended into the gut, liver, and cardiovascular system, suggesting the cytoprotective activity isnt confined to one tissue type but reflects a broader mechanism (Jozwiak et al., 2025) For research use only

Hesitation makes it hurt more

Clinics such as Toniik highlight the benefits of combining medical approaches with evidence-based lifestyle changes to maximise results

2007;51(8):1404-1412 Chihara K, Minamitani N, Kaji H, et al

Or am I simply relying on the GLP-1 to do the work